Company Overview
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Why Investors Should Care
Revenue has grown at a 75.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $42.73M (-60.5% YoY); net profit $-204.38M.
- Trailing 12 Months Year-on-year growth — revenue -73.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 75.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 75.75% |
| 1 Year: | -73.90% |
Stock Price Performance
| 1 Year: | -44.52% |
| 6 Months: | -62.96% |
| 3 Months: | -15.18% |
| 1 Month: | -19.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 75.8% over 5 years.
CONS
- Trading 77.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WVE Wave Life Sciences Ltd. R2KR3KPHARMA | 4.86 | -4.50 | $957.65M | 0.00% | -39.63% | -67.42% | 75.75% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 383.00K | 1.10M | 1.31M | 1.10M | 1.42M | 4.88M | 4.49M | 3.62M | 3.03M | 7.63M | 2.93M | 2.40M | 4.16M | 3.03M | 3.45M | - | 2.78M | 36.42M | 1.75M | 375.00K | 285.00K | 12.93M | 22.11M | 49.21M | 12.54M | 19.69M | - | - | 9.18M | 8.70M | 7.61M | 17.25M | 38.25M | 2.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 58.98M | 61.46M | 63.96M | 73.71M | 69.54M | - |
| Operating Income | -4.99M | -7.21M | -7.95M | -11.64M | -17.23M | -18.50M | -20.21M | -24.67M | -26.35M | -31.16M | -35.77M | -36.57M | -38.23M | -48.94M | -47.99M | -45.62M | -54.18M | -60.53M | -49.99M | -38.66M | -34.41M | -43.47M | -39.83M | -7.61M | -38.09M | -42.16M | -38.90M | -30.29M | -23.47M | 4.44M | -34.46M | -35.00M | -63.91M | - | -49.80M | -52.76M | -56.35M | -56.47M | -31.30M | -73.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -47.64M | -50.56M | -54.12M | -54.20M | -28.99M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -46.88M | -50.47M | -53.85M | -53.18M | -26.09M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -4.94M | -7.10M | -7.85M | -11.56M | -17.54M | -18.45M | -21.10M | -24.60M | -25.49M | -30.79M | -35.24M | -35.89M | -37.63M | -37.89M | -44.20M | -41.94M | -50.73M | -56.77M | -47.49M | -40.53M | -33.10M | -42.46M | -38.77M | -6.23M | -37.81M | -41.30M | -39.00M | -27.41M | -21.10M | 7.25M | -31.56M | -32.92M | -61.78M | - | -46.88M | -50.47M | -53.85M | -53.18M | -26.09M | -69.36M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.78 | -0.12 | -0.62 | -0.62 | -0.42 | -0.27 | -0.20 | 0.07 | -0.24 | -0.25 | -0.47 | - | -0.29 | -0.31 | -0.32 | -0.30 | -0.13 | -0.34 |
| R&D Expense | 2.13M | - | 4.74M | 8.40M | 13.69M | - | 14.74M | 19.10M | 20.10M | - | 29.20M | 32.55M | 32.88M | - | 40.11M | 41.60M | 44.59M | - | 41.16M | 31.48M | 28.27M | 33.39M | 31.64M | 31.09M | 27.47M | 29.73M | 27.57M | 30.98M | 33.31M | 31.64M | 33.45M | 40.39M | 41.20M | - | 40.62M | 43.47M | 45.87M | - | 47.44M | 51.29M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 152.00K | 1.09M | 3.89M | 14.41M | 15.98M | 20.08M | 40.96M | 3.65M | 113.31M | 108.30M | 42.73M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 166.37M | 181.30M | 218.71M | 258.11M |
| Operating Income | -3.57M | -5.39M | -19.30M | -55.72M | -102.39M | -159.52M | -208.32M | -153.38M | -127.02M | -162.72M | -68.00M | -110.40M | -215.38M |
| EBITDA | - | - | - | - | - | - | - | - | - | -152.61M | -58.79M | -101.74M | -206.53M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -161.14M | -58.19M | -97.01M | -204.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 681.00K | -677.00K | 0 | 0 |
| Net Income | -3.32M | -5.23M | -19.20M | -55.66M | -101.98M | -146.65M | -193.64M | -149.91M | -122.25M | -161.82M | -57.51M | -97.01M | -204.38M |
| Diluted EPS | - | - | - | - | - | - | - | - | -2.36 | -2.05 | -0.54 | -0.70 | -1.21 |
| R&D Expense | 1.92M | 2.40M | 9.06M | 40.82M | 79.31M | 134.43M | 175.43M | 130.94M | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.94M | 165.42M | 164.81M | 181.84M | 295.94M | 284.25M | 279.24M | 207.01M | 146.39M | 274.95M | 352.21M | 638.50M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 98.54M | 235.37M | 320.39M | 614.81M |
| Cash & Equivalents | 379.00K | 439.00K | 1.05M | 161.22M | 150.29M | 142.50M | 174.82M | 147.16M | 184.50M | 150.56M | 88.50M | 200.35M | 302.08M | 602.07M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 0 | 21.09M | 1.42M | 1.28M |
| Total Liabilities | - | - | 911.00K | 4.06M | 22.07M | 34.36M | 214.72M | 212.64M | 188.59M | 166.63M | 191.48M | 235.32M | 142.69M | 120.14M |
| Current Liabilities | - | - | 882.00K | 3.82M | 12.15M | 18.19M | 130.04M | 118.15M | 121.04M | 64.20M | 71.52M | 186.44M | 110.95M | 95.06M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 37.61M | 32.12M | 25.40M | 17.77M |
| Total Equity | -4.58M | -7.76M | 2.03M | 153.49M | 134.60M | 139.61M | 73.35M | 63.73M | 82.78M | 32.50M | -45.09M | 39.63M | 209.51M | 518.36M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 86.92M | 119.16M | 153.04M | 187.66M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -31.93M | -83.67M | -22.86M | -188.23M | -115.98M | - | -127.78M | -19.43M | -151.03M | -187.49M |
| Investing Cash Flow | - | - | - | -5.56M | -18.89M | -9.94M | -3.92M | -1.34M | - | -1.25M | -1.11M | -938.00K | -718.00K |
| Financing Cash Flow | - | - | - | 29.12M | 94.37M | 65.09M | 164.40M | 154.54M | - | 67.19M | 132.53M | 253.89M | 488.24M |
| Capital Expenditure | -47.00K | -590.00K | -1.86M | -5.57M | -18.89M | -9.94M | -3.92M | -1.34M | - | -1.36M | -1.11M | -938.00K | -718.00K |
| Free Cash Flow | - | - | - | -37.49M | -102.56M | -32.80M | -192.15M | -117.32M | - | -129.14M | -20.55M | -151.96M | -188.21M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -61.85M | 111.99M | 101.93M | 300.02M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -12,696.1% | -5,102.6% | -2,630.1% | -1,106.7% | -1,303.4% | -763.9% | -310.1% | -4,459.3% | -60.0% | -101.9% | -504.1% |
| Net Margin % | - | - | -12,631.6% | -5,097.1% | -2,619.6% | -1,017.4% | -1,211.5% | -746.7% | -298.4% | -4,434.7% | -50.8% | -89.6% | -478.3% |
| ROE % | 42.7% | -258.0% | -12.5% | -41.4% | -73.0% | -199.9% | -303.8% | -181.1% | -376.2% | 358.9% | -145.1% | -46.3% | -39.4% |
| ROCE % | - | -262.4% | -11.9% | -36.5% | -62.6% | -96.2% | -125.4% | -97.0% | -88.9% | -217.4% | -76.8% | -45.8% | -39.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kennedy Capital Management, LLC | - | 429.12K | $2.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WVE
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Pau…
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant move…
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (…
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that memb…
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials.
WAVE Life Sciences Q2 Earnings Call Highlights
WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026. The com…
WVE — Frequently Asked Questions
What is the current share price of Wave Life Sciences Ltd. (WVE)?
As of 2026-09-07 16:24 PDT, Wave Life Sciences Ltd. (WVE) trades at $4.86 on NasdaqGM. Its 52-week range is $4.70 to $21.31.
What is the market capitalisation of WVE?
Wave Life Sciences Ltd. (WVE) has a market capitalisation of $957.65M on NasdaqGM.
What is the P/E ratio of WVE?
WVE trades at a trailing price-to-earnings (P/E) ratio of -4.50. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.21.
What is the return on equity (ROE) of WVE?
WVE has a return on equity (ROE) of -67.42%. Its return on capital employed (ROCE) is -39.63%.
Is WVE a good stock to buy?
This page provides a data-driven analysis of Wave Life Sciences Ltd. (WVE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.